SAMRA TURAJLIC

Group Leader at The Francis Crick Institute, Professor at the Institute of Cancer Research and Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust

Samra Turajlic is a prominent medical oncologist and cancer researcher who holds several key positions in the field of cancer research and treatment. Here are some key details about her:

Education and Career

Samra Turajlic completed her undergraduate medical studies at Oxford University and her clinical training at UCL Medical School.1 2 She gained her PhD in 2013 from the Institute of Cancer Research, focusing on melanoma genetics and targeted therapy resistance.2 4

In 2014, she was awarded a Cancer Research UK Clinician Scientist Fellowship to study cancer evolution at the Francis Crick Institute.4 She completed her training in medical oncology in 2015 and was appointed as a Consultant Medical Oncologist at the Royal Marsden, specializing in the treatment of skin and urological cancers.1 4

Current Positions

Group Leader at the Francis Crick Institute, where she leads the cancer dynamics lab1 5
Consultant Medical Oncologist at the Royal Marsden, specializing in kidney cancer and melanoma4
Professor at The Institute of Cancer Research, London (conferred in October 2022)4

Research Focus

Professor Turajlic's research primarily focuses on understanding cancer evolution and its implications for patient care. Her key areas of study include:

Kidney cancer evolution through the TRACERx Renal project1 2
Melanoma metastasis1
Von Hippel-Lindau disease1
Development of representative sequencing techniques for tumor analysis1

Achievements and Roles

Chief Investigator of translational studies into melanoma and kidney cancer (TRACERx)2 5
Member of various scientific committees and faculty groups, including ESMO and NCRI2 4
Trustee of the Kidney Cancer Support Network and Melanoma Focus1 2
Senior Editor at Macmillan Cancer Support1 2
Recipient of the ESMO Translational Research Award in 20223
Named in "50 Movers and Shakers in Bio-business" in 20183
Co-inventor on three patents arising from her research discoveries3

Professor Turajlic's work has been widely recognized and cited, with her research contributing significantly to the understanding of cancer evolution and its implications for patient treatment.